Roche (RHHBY) is increasing its investment into the obesity space with an up to $5.3 billion deal with Danish drugmaker Zealand Pharma (ZLDPF), the companies announced Wednesday. The deal would give ...
Despite comments made by a Novo Nordisk official this week, the company confirmed to BioSpace that it has no additional ...
Novo Nordisk’s vision of 25%-plus weight loss is looking further and further away. | Novo Nordisk’s vision of 25%-plus weight ...
Analysts acknowledged the long-term manufacturing deal could dull Viking’s takeout prospects but hailed it as a smart move to ensure supply.
Eli Lilly plans to launch Mounjaro, its blockbuster diabetes drug, in countries like China, India, Brazil and Mexico by 2026, ...
As the global demand for obesity treatments skyrockets, Vikrant Shrotriya discusses the complex nature of obesity, the ...
Roche and Zealand reason petrelintide could deliver weight loss comparable to glucagon-like peptide 1 (GLP-1) receptor ...
GlobalData on MSN1d
Asceletis’ muscle-preserving weight loss therapy sustains 40-day half-lifeThe company’s weight loss therapy was able to sustain itself for up to 40 days in obese patients after a single injection.
Research suggests potential health benefits beyond what popular diabetes and weight-loss drugs were first approved to treat.
Companies in the US, including Novo Nordisk, Boeing and Shein, are forming task forces to address the impact of Donald ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback